SLT Holdings LLC Invests $66,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SLT Holdings LLC bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ESPR. Wasatch Advisors LP increased its position in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. Geode Capital Management LLC increased its position in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares during the period. State Street Corp increased its position in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares during the period. JPMorgan Chase & Co. increased its position in Esperion Therapeutics by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after buying an additional 19,588 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 295,378 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $1.69 on Friday. Esperion Therapeutics, Inc. has a 1-year low of $1.56 and a 1-year high of $3.94. The company has a market cap of $332.99 million, a PE ratio of -2.64 and a beta of 1.04. The stock’s 50 day moving average price is $1.96 and its 200 day moving average price is $2.08.

Analyst Ratings Changes

Several research firms have commented on ESPR. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.